Pre-made Enoticumab benchmark antibody ( Whole mAb, anti-DLL4 therapeutic antibody, Anti-AOS6/delta4/hdelta2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-186

Pre-Made Enoticumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enoticumab (REGN421, INN) is a human monoclonal antibody that binds to DLL4. It acts as an immunomodulator.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-186-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Enoticumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody
INN Name Enoticumab
TargetDLL4
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesRegeneron Pharmaceuticals;Sanofi
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development TechVelocImmune Mouse